NCT06827899View on ClinicalTrials.gov

Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG)

Specified dose on specified days

Trial Locations (1)

361000

RECRUITING

Bing Xu, Xiamen

All Listed Sponsors
collaborator

Fujian Provincial Hospital

OTHER

collaborator

Fujian Cancer Hospital

OTHER_GOV

collaborator

Zhangzhou Affiliated Hospital of Fujian Medical University

OTHER

collaborator

Jieyang People's Hospital

OTHER

collaborator

Huizhou Municipal Central Hospital

OTHER

lead

The First Affiliated Hospital of Xiamen University

OTHER